Activation of mitogen-activated protein kinase by the nociceptin receptor expressed in Chinese hamster ovary cells  by Fukuda, Kazuhiko et al.
FEBS Letters 412 (1997) 290-294 FEBS 18963 
Activation of mitogen-activated protein kinase by the nociceptin receptor 
expressed in Chinese hamster ovary cells 
Kazuhiko Fukuda*, Takehiro Shoda, Hitoshi Morikawa, Shigehisa Kato, Kenjiro Mori 
Department of Anesthesia, Kyoto University Hospital, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-01, Japan 
Received 12 June 1997 
Abstract Activation of the nociceptin receptor stably expressed 
in Chinese hamster ovary cells induced a transient mitogen-
activated protein kinase (MAPK) activation, via pertussis toxin-
sensitive G-proteins. The nociceptin receptor-mediated MAPK 
activation was partially blocked by down-regulation or inhibition 
of protein kinase C, and suppressed by pretreatment with a 
phosphatidylcholine-specific phospholipase C inhibitor, D609. 
Furthermore, a tyrosine protein kinase inhibitor, genistein, and 
phosphatidylinositol 3-kinase inhibitors, wortmannin and 
LY294002, affected the nociceptin-induced MAPK activity. 
The nociceptin-induced MAPK activation may lead to activation 
of phospholipase A2 and induce changes in gene expression. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The opioid receptor mediates a variety of pharmacological 
effects of opioid analgesics. cDNAs encoding the three major 
types of the opioid receptor, 8, u. and K, have been cloned and 
sequenced [1]. In addition, several laboratories have cloned 
the c D N A encoding an opioid receptor homolog, ORL1 [2], 
R O R - C [3] or LCI32 [4], by cross-hybridization or polymer-
ase chain reaction. Recently, a peptide nociceptin [5], also 
designated as orphanin F Q [6], has been isolated from brain 
tissue, on the basis of its ability to inhibit adenylate cyclase in 
Chinese hamster ovary (CHO) cells stably transfected with the 
ORL1 cDNA. Nociceptin is constituted from 17 amino acid 
residues and its amino acid sequence resembles that of an 
endogenous opioid peptide, dynorphin A [5,6]. When injected 
intracerebroventricularly or intrathecally into mice, nociceptin 
induced hyperalgesia and allodynia, in contrast to antinoci-
ceptive action of opioid peptides [5-7]. Thus, despite its struc-
tural similarity to opioid peptides, nociceptin appears to be 
pharmacologically and physiologically distinct from them. 
Molecular basis for the nociceptin actions has been exam-
ined using neuronal cells endogenously expressing the noci-
ceptin receptor. Electrophysiological studies demonstrated 
that activation of the nociceptin receptor expressed in hippo-
campal neurons and a neuroblastoma cell line leads to inhi-
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bition of the voltage-dependent Ca 2 + channel activity [8,9]. 
Furthermore, it has been shown that nociceptin increases in-
wardly rectifying K + conductance in dorsal raphe nucleus 
neurons [10]. 
Mitogen-activated protein kinase (MAPK) , also known as 
extracellular signal-regulated kinase (ERK) is a central com-
ponent of an evolutionarily conserved kinase cascade, which 
integrates various extracellular signals converging to it [11,12]. 
It has been shown that M A P K is activated by G-protein-
coupled receptors as well as tyrosine kinase receptors [12]. 
We have previously reported that activation of the 5-, u-
and K-opioid receptors expressed in C H O cells elicits 
M A P K activation through the action of pertussis toxin 
(PTX)-sensitive G-proteins [13]. In this investigation, in order 
to gain a further insight into the molecular basis of the noci-
ceptin action, we examined functional coupling of the noci-
ceptin receptor with M A P K . The results obtained indicate 
that activation of the nociceptin receptor expressed in C H O 
cells induces M A P K activation via PTX-sensitive G-proteins. 
2. Materials and methods 
2.1. cDNA expression 
The 1.7-kb Hindlll fragment from the plasmid pROR30 [3], carry-
ing the entire protein coding sequence of the nociceptin receptor 
(ROR-C), was cloned into an expression vector pcDNA3 (Invitrogen) 
in the same orientation with respect to the cytomegalovirus promoter 
to generate pcDNA3ROR-C. 
CHO cells were transfected with pcDNA3ROR-C by the calcium 
phosphate method [14]. To isolate clones expressing the nociceptin 
receptor, clones resistant to 600 Jig/ml G418 were screened by RNA 
blot hybridization analysis. 
2.2. [3Hj'Nociceptin binding assay 
Crude membranes were prepared as in [13]. Binding reaction was 
performed with membrane preparations (15-30 |ig of protein) in 0.2 ml 
of 50 mM Tris-HCl, pH 7.5, containing 0.1% bovine serum albumin 
at 30°C for 1 h in the presence of various concentrations of 
[3H]nociceptin (173 Ci/mmol; Amersham). After incubation, the sam-
ples were collected on polyethyleneimine-treated GF/B filters (What-
man) and washed with 10 ml of ice-cold 50 mM Tris-HCl, pH 7.5. 
The filters were then counted for radioactivity. Non-specific binding 
was determined with 1 uM nociceptin. The protein concentration in 
the membrane preparation was measured as in [15]. 
2.3. Assay of MAPK activity 
Cells were grown to subconfluence in 60-mm dishes, serum-starved 
for 24 h, and stimulated by nociceptin at 37°C for the indicated times. 
Preparation of cell lysates and assay for the MAPK activity were 
performed as in [13]. The protein concentration in the cell lysate 
was measured as in [15], and the MAPK activity was expressed as 
pmol/min/mg protein. 
2.4. Immunoblot analysis 
Cell lysates were prepared as in [13]. Samples were electrophoresed 
on an SDS-10% polyacrylamide gel and transferred to a polyvinyl-
idene difluoride membrane. After blocking for 1 h in the buffer TBS-T 
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(20 mM Tris-HCl (pH 7.5), 137 mM NaCl and 0.1% Tween-20) con-
taining 5% non-fat dry milk, the membrane was incubated for 2 h at 
room temperature with phospho-specific MAPK antibody (New Eng-
land Biolabs) diluted 1:1000 in TBS-T containing 5% non-fat dry 
milk, and then incubated for 1 h with a horseradish peroxidase-con-
jugated secondary antibody. After washing with TBS-T, the protein-
antibody complex was visualized using the enhanced chemilumines-
cence detection system (Amersham). 
2.5. Statistics 
Data are expressed as mean ± SEM. Statistical analyses of data 
were performed by ANOVA followed by Fisher's protected least sig-
nificance difference test. Values of P < 0.05 were considered to be 
statistically significant. 
3. Results 
CHO cells were stably transfected with the cloned cDNA 
for the nociceptin receptor (ROR-C) [3], and a clone, CROR-
C39, was selected for further analysis. The membrane prepa-
ration from CROR-C39 was subjected to the [3H]nociceptin 
binding assay. Fig. 1 shows that ROR-C expressed in CHO 
cells bound nociceptin with a high affinity, whereas negligible 
binding was found for non-transfected CHO cells. Scatchard 
analysis demonstrated that the K& value for nociceptin of the 
expressed receptor is 1.2±0.1 nM (meantSEM; n = 3), and 
that the Bmax value is 5.1 ±0.8 pmol/mg protein (» = 3). 
As shown in Fig. 2A, MAPK activity in cell lysates pre-
pared from CROR-C39 was increased to ~ 10-fold of the 
non-stimulation control level at 3-5 min after the addition 
of 100 nM nociceptin, and thereafter declined gradually. On 
the other hand, 100 nM nociceptin did not elicit significant 
MAPK activation in non-transfected CHO cells (data not 
shown). The MAPK activity evoked by stimulation with no-
ciceptin for 5 min was dose-dependent (Fig. 2B), and the 
maximal activation (10.4 ± 2.2-fold of the non-stimulation 
control value, n = A) was observed at 1 |iM nociceptin. The 
EC50 value was 11.1 ± 1.7 nM (w = 4). Treatment of the cells 
with 100 ng/ml PTX for 12 h completely abolished the ability 
of nociceptin to activate MAPK (Fig. 2C), indicating that the 
response is mediated by PTX-sensitive G-proteins (Gi and/or 
G0). An opioid antagonist naloxone (10 uM) did not signifi-
cantly affect the nociceptin-induced MAPK activity (Fig. 2C), 
in accordance with the reports that the nociceptin receptor 
does not show high affinity for opioid ligands, in spite of 
high homology in amino acid sequence between the nociceptin 
receptor and the opioid receptors [2-4]. 
MAPKs, consisting of two isoforms p44 (ERK1) and p42 
(ERK2), exist as unphosphorylated forms in non-stimulated 
cells and become activated when both tyrosine and threonine 
residues are phosphorylated by MAPK/ERK kinase (MEK) 
[11,12,16]. Consistently, pre-incubation of the cells with 50 |t,M 
PD98059 [17], a specific MEK inhibitor, for 2 h almost com-
pletely abolished the nociceptin-induced MAPK activity (Fig. 
2C). Furthermore, as shown in Fig. 3A, stimulation of 
CROR-C39 cells with nociceptin induced appearance of phos-
phorylated forms of p44 and p42 MAPKs in a time-dependent 
manner, whereas phosphorylated MAPKs were not detectable 
in non-stimulated control cells. p44 and p42 MAPKs became 
maximally phosphorylated at 3-5 min of stimulation. Fig. 3B 
shows that the appearance of phosphorylated MAPKs is de-
pendent on the nociceptin concentration. Maximal phospho-
rylation of p44 and p42 MAPKs was observed in the range 
from 100 nM to 1 |xM nociceptin. Thus, the time course and 
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Fig. 1. Saturation analysis of [3H]nociceptin binding. Membrane 
preparations from CHO cells expressing the nociceptin receptor, 
CROR-C39 (•), and non-transfected CHO cells (o) were subjected 
to saturation analysis of [3H]nociceptin binding. The inset shows 
Scatchard plot of the data. Representative result from three separate 
experiments is shown. 
the dose dependence of nociceptin-induced MAPK phospho-
rylation paralleled with those of the nociceptin-induced in-
crease in MAPK activity. 
As shown in Fig. 4A, the MAPK activation induced by 
nociceptin was partially ( ~ 25%) suppressed by protein kinase 
C (PKC) down-regulation induced by treatment with 1 u,M 
phorbol 12-myristate 13-acetate (PMA) for 18 h. Fig. 4A also 
shows that PKC inhibition by pretreatment for 4 h with 1 jiM 
GF 109203X [18], partially (~25%) inhibited the nociceptin-
induced MAPK activation. These results suggest that the 
MAPK activation mediated by the nociceptin receptor is at 
least partially dependent on PKC activation. It is not likely 
that the nociceptin receptor induces PKC activation through 
production of diacylglycerol from phosphatidylinositol 4,5-
bisphosphate, because nociceptin did not induce significant 
elevation of the cellular level of inositol 1,4,5-trisphosphate 
(data not shown), indicating that phosphatidylinositol-specific 
phospholipase C is not significantly activated by nociceptin. 
Therefore, we tested the possible involvement of phosphati-
dylcholine-specific phospholipase C (PC-PLC), since it has 
been reported that diacylglycerol derived from phosphatidyl-
choline (PC) can activate PKC [19]. Pretreatment of the cells 
for 2 h with 50 uM D609 [20], a specific PC-PLC inhibitor, 
suppressed the nociceptin-induced MAPK activation (Fig. 
4A). This result suggests the involvement of PC-PLC in the 
signaling pathway of MAPK activation mediated by the no-
ciceptin receptor. 
Pretreatment of CROR-C39 cells for 2 h with 200 uM gen-
istein, a tyrosine protein kinase inhibitor, partially inhibited 
the nociceptin-induced MAPK activation, although statisti-
cally not significant (Fig. 4A). In the cells in which PKC 
was down-regulated by treatment with 1 u\M PMA for 18 h, 
genistein reduced the nociceptin-induced MAPK activity 
nearly to the prestimulation level, suggesting that tyrosine 
protein kinase is involved in the PKC-independent component 
of the nociceptin-evoked MAPK activation. Fig. 4B demon-
strates that the nociceptin-induced MAPK activation was par-
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tially (30-40%) inhibited by pretreatment of the cells for 2 h 
with phosphatidylinositol 3-kinase (PI3K) inhibitors, 1 uM 
wortmannin [21] or 1 uM LY294002 [22]. In the cells pre-
treated with 1 u\M PMA for 18 h to down-regulate PKC, 
wortmannin almost completely suppressed the nociceptin-
induced MAPK activation. These results suggest that PI3K 
takes part in the nociceptin-induced MAPK activation 
through the PKC-independent pathway. 
4. Discussion 
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Fig. 3. Immunoblot analysis using the antibody specific for the 
phosphorylated MAPKs. CHO cells expressing the nociceptin recep-
tor, CROR-C39, were stimulated for the indicated times with 
100 nM nociceptin (A), and for 5 min with the indicated concentra-
tions of nociceptin (B). Cell lysates were subjected to immunoblot 
analysis using the phospho-specific MAPK antibody. Representative 
results from three separate experiments are shown. The positions of 
phosphorylated forms of MAPKs (p44 and p42) are as indicated. C, 
non-stimulation control. 
G-protein-coupled receptors mediate activation of MAPKs 
via the heterotrimeric G-protein [12] through different mech-
anisms. MAPK activation by the G;-coupled receptors, in-
cluding the m2 muscarinic acetylcholine receptor and the 
c«2A adrenergic receptor, is mediated by the py subunits of 
the G-proteins, Ras and Raf kinase in a PKC-independent 
manner, and is inhibited by pretreatment with tyrosine protein 
kinase inhibitors [23,24]. On the other hand, it has been re-
cently shown that the ml muscarinic acetylcholine receptor 
and the platelet-activating factor receptor couple with G0 to 
activate MAPK by a PKC-dependent and Ras-independent 
mechanism [25]. Therefore, our finding that the nociceptin 
receptor mediates MAPK activation through the action of 
PTX-sensitive G-proteins (G; and/or G0) via PKC-dependent 
and -independent pathways may suggest that the nociceptin 
receptor couples with G0 and G;, which activates MAPK 
through PKC-dependent and -independent mechanism, re-
spectively. Moreover, the involvement of tyrosine protein ki-
nase and PI3K in the PKC-independent pathway of the noci-
ceptin-induced MAPK activation agrees with the recent report 
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Fig. 2. MAPK activity induced by activation of the nociceptin receptor expressed in CHO cells. A: Time course of the nociceptin-induced 
MAPK activity. CHO cells expressing the nociceptin receptor, CROR-C39, were stimulated by 100 nM nociceptin for the indicated times. Each 
point represents the mean ± SEM from four separate experiments. B: Dose-response relationship for the nociceptin receptor-mediated MAPK 
activation. CROR-C39 cells were stimulated by nociceptin at the indicated concentrations for 5 min. Each point represents the mean ± SEM 
from eight separate experiments. C: Effects of naloxone, PTX and PD98059 on the nociceptin-induced MAPK activation. CROR-C39 cells 
were treated with 100 ng/ml PTX for 12 h, 10 uM naloxone for 10 min or 50 uM PD98059 for 2 h, and then stimulated with 100 nM nocicep-
tin for 5 min. Data are mean ± SEM values from eight separate experiments. Significantly different from the control value with neither pretreat-
ment nor nociceptin stimulation; 'significantly different from the MAPK activity evoked by nociceptin without pretreatment. 
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Fig. 4. Effects of pretreatments on the nociceptin-induced MAPK activity. With or without pretreatment, CHO cells expressing the nociceptin 
receptor, CROR-C39, were stimulated for 5 min with 100 nM nociceptin. Data are mean±SEM values from eight separate experiments. 
Significantly different from the control value with neither pretreatment nor stimulation; 'significantly different from the MAPK activity evoked 
by nociceptin without pretreatment. A: Effects of inhibition of PKC, PC-PLC, and tyrosine protein kinase on the nociceptin-induced MAPK 
activity. Pretreatment of the cells were as follows: 1 uM PMA for 18 h; 1 uM GF 109203X for 4 h; 50 uM D609 for 2 h; 200 uM genistein 
for 2 h; the combination of 1 uM PMA for 18 h and 200 uM genistein for 2 h. B: Effects of PI3K inhibitors on the nociceptin-induced 
MAPK activity. Pretreatment of the cells were as follows: 1 uM wortmannin for 1 h; 1 uM LY294002 for 1 h; the combination of 1 uM 
PMA for 18 h and 1 |xM wortmannin for 1 h. 
that PI3Ky mediates MAPK signaling activated by G-protein 
Py subunits in a tyrosine protein kinase-dependent fashion 
[26]. 
D609, an inhibitor of PC-PLC [20], suppressed the MAPK 
activity induced by nociceptin, suggesting that PKC is acti-
vated by diacylglycerol derived from PC, resulting in PKC-
dependent MAPK activation. This finding agrees with the 
recent report that PC-PLC represents a component of 
the mechanism by which MAPK is activated by the 
5-hydroxytryptaminexA receptor expressed in CHO cells 
[27]. The inhibitory effect of D609 on nociceptin-induced 
MAPK activity was more remarkable than that of PKC 
inhibition by GF 109203X and PKC down-regulation by 
prolonged treatment with PMA. This result may suggest 
that PC-PLC is also involved in the PKC-independent 
pathway. In agreement with this speculation, it has been 
reported that PC hydrolysis by PC-PLC acts upstream of 
Raf kinase and serves to couple Ras to Raf kinase activation, 
suggesting the possibility that PC-derived diacylglycerol 
functions directly as a Raf kinase activator without PKC ac-
tivation [28]. Further study is required to elucidate the mech-
anism for PC-PLC activation mediated by the nociceptin re-
ceptor. 
Activation of MAPKs by the nociceptin receptor in neuro-
nal cells may lead to important cellular responses. Cytosolic 
phospholipase A2, which hydrolyzes arachidonic acid from 
membrane phospholipids, represents an important target of 
the MAPK signal transduction pathway, and activated by 
phosphorylation by MAPKs [16]. Therefore, activation of 
the nociceptin receptor may induce an increase in production 
of eicosanoids, by activation of phospholipase A2 via 
MAPKs. Moreover, MAPKs phosphorylate and regulate a 
variety of transcription factors, including c-Myc, c-Jun, 
c-Fos and ATF-2 [16]. Thus, it is conceivable that activation 
of the nociceptin receptor induces alterations in gene expres-
sion via MAPK activation, resulting in long-term changes in 
neuronal function. 
In conclusion, our results indicate that the nociceptin re-
ceptor expressed in CHO cells functionally couples with the 
MAPK cascade in a PTX-sensitive manner, and suggest that 
294 K. Fukuda et al.lFEBS Letters 412 (1997) 290-294 
PKC, PC-PLC, tyrosine kinase and PI3K are involved in the 
nociceptin-induced MAPK activation. 
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